Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian P Booth

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Bioanalysis|July 12, 2018
Hybrid assays: the next big thing?Brian P Booth, Brian Furmanski
Journal of Clinical Pharmacology|November 15, 2003
Considerations in analyzing single-trough concentrations using mixed-effects modelingBrian P Booth, Jogarao V S Gobburu
The AAPS Journal|July 4, 2013
Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests?Hongying Gao, Abigail Jacobs, Ronald E White, et al.
The AAPS Journal|October 24, 2020
Land O'Lakes Workshop on Microsampling: Enabling Broader AdoptionEnaksha R Wickremsinhe, Qin C Ji, Carol R Gleason, et al.
Journal of Patient-Reported Outcomes|November 17, 2023
Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug developmentHuiming Xia, Brian P Booth, Yaning Wang, et al.
Journal of Clinical Pharmacology|December 29, 2006
Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patientsBrian P Booth, Atiqur Rahman, Ramzi Dagher, et al.
Bioanalysis|November 19, 2010
10th Annual University of Wisconsin Land O'Lakes Bioanalytical ConferenceJames E DeMuth, Mark E Arnold, Brian P Booth, et al.
Bioanalysis|November 24, 2012
Conference report: emerging technology for bioanalysis in the next decadeJames E Demuth, Qin C Ji, Brian P Booth, et al.
Journal of Clinical Pharmacology|December 29, 2006
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicityRoshni P Ramchandani, Yaning Wang, Brian P Booth, et al.
Biopharmaceutics & Drug Disposition|January 25, 2012
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practiceJoseph A Grillo, Ping Zhao, Julie Bullock, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Bioanalysis|July 12, 2018
Hybrid assays: the next big thing?Brian P Booth, Brian Furmanski
Journal of Clinical Pharmacology|November 15, 2003
Considerations in analyzing single-trough concentrations using mixed-effects modelingBrian P Booth, Jogarao V S Gobburu
The AAPS Journal|July 4, 2013
Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests?Hongying Gao, Abigail Jacobs, Ronald E White, et al.
The AAPS Journal|October 24, 2020
Land O'Lakes Workshop on Microsampling: Enabling Broader AdoptionEnaksha R Wickremsinhe, Qin C Ji, Carol R Gleason, et al.
Journal of Patient-Reported Outcomes|November 17, 2023
Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug developmentHuiming Xia, Brian P Booth, Yaning Wang, et al.
Journal of Clinical Pharmacology|December 29, 2006
Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patientsBrian P Booth, Atiqur Rahman, Ramzi Dagher, et al.
Bioanalysis|November 19, 2010
10th Annual University of Wisconsin Land O'Lakes Bioanalytical ConferenceJames E DeMuth, Mark E Arnold, Brian P Booth, et al.
Bioanalysis|November 24, 2012
Conference report: emerging technology for bioanalysis in the next decadeJames E Demuth, Qin C Ji, Brian P Booth, et al.
Journal of Clinical Pharmacology|December 29, 2006
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicityRoshni P Ramchandani, Yaning Wang, Brian P Booth, et al.
Biopharmaceutics & Drug Disposition|January 25, 2012
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practiceJoseph A Grillo, Ping Zhao, Julie Bullock, et al.
Pageof 3